via Rensselaer Polytechnic Institute
Heparin, a common anticoagulant, could also form the basis of a viral trap for SARS-CoV-2
In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease. Heparin, a common blood thinner, and a heparin variant stripped of its anticoagulant properties, performed on par with remdesivir in inhibiting SARS-CoV-2 infection in mammalian cells.
Published online today in Cell Discovery, the research is the latest example of a decoy strategy researchers from the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselear Polytechnic Institute are developing against viruses like the novel coronavirus that spawned the current global health crisis.
The spike protein on the surface of SARS-CoV-2 latches onto the ACE-2 receptor, a molecule on the surface of human cells. Once secured, the virus inserts its own genetic material into the cell, hijacking the cellular machinery to produce replica viruses. But the virus could just as easily be persuaded to lock onto a decoy molecule that offers a similar fit. The neutralized virus would be trapped and eventually degrade naturally.
Previous research has shown this decoy technique works in trapping other viruses, including dengue, Zika, and influenza A.
“We’re learning how to block viral infection, and that is knowledge we are going to need if we want to rapidly confront pandemics,” said Jonathan Dordick, the lead researcher and a professor of chemical and biological engineering at Rensselaer Polytechnic Institute. “The reality is that we don’t have great antivirals. To protect ourselves against future pandemics, we are going to need an arsenal of approaches that we can quickly adapt to emerging viruses.”
The Cell Discovery paper tests antiviral activity in three variants of heparin (heparin, trisulfated heparin, and a non-anticoagulant low molecular weight heparin) and two fucoidans (RPI-27 and RPI-28) extracted from seaweed. All five compounds are long chains of sugar molecules known as sulfated polysaccharides, a structural conformation that the results of a binding study published earlier this month in Antiviral Research suggested as an effective decoy.
The researchers performed a dose response study known as an EC50 — shorthand for the effective concentration of the compound that inhibits 50% of viral infectivity — with each of the five compounds on mammalian cells. For the results of an EC50, which are given in a molar concentration, a lower value signals a more potent compound.
RPI-27 yielded an EC50 value of approximately 83 nanomolar, while a similar previously published and independent in vitro test of remdesivir on the same mammalian cells yielded an EC50 of 770 nanomolar. Heparin yielded an EC50 of 2.1 micromolar, or about one-third as active as remdesivir, and a non-anticoagulant analog of heparin yielded an EC50 of 5.0 micromolar, about one-fifth as active as remdesivir.
A separate test found no cellular toxicity in any of the compounds, even at the highest concentrations tested.
“What interests us is a new way of getting at infection,” said Robert Linhardt, a Rensselaer professor of chemistry and chemical biology who is collaborating with Dordick to develop the decoy strategy. “The current thinking is that the COVID-19 infection starts in the nose, and either of these substances could be the basis for a nasal spray. If you could simply treat the infection early, or even treat before you have the infection, you would have a way of blocking it before it enters the body.”
Dordick added that compounds from seaweed “could serve as a basis for an oral delivery approach to address potential gastrointestinal infection.”
In studying SARS-CoV-2 sequencing data, Dordick and Linhardt recognized several motifs on the structure of the spike protein that promised a fit compatible with heparin, a result borne out in the binding study. The spike protein is heavily encrusted in glycans, an adaptation that protects it from human enzymes which could degrade it, and prepares it to bind with a specific receptor on the cell surface.
“It’s a very complicated mechanism that we quite frankly don’t know all the details about, but we’re getting more information,” said Dordick. “One thing that’s become clear with this study is that the larger the molecule, the better the fit. The more successful compounds are the larger sulfated polysaccharides that offer a greater number of sites on the molecules to trap the virus.”
Molecular modeling based on the binding study revealed sites on the spike protein where the heparin was able to interact, raising the prospects for similar sulfated polysaccharides.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Coronavirus decoy strategy
- COVID-19 virus disrupts protein production: Researcher discusses her recent findings
Despite huge advances in our understanding of COVID-19 over the past four years, the disease is still very much among us—and there remains a lot to learn.
- Russia's aircraft decoy strategy fails to fool Ukrainian intelligence
At Kirovske Airfield on occupied Crimea there are decoy Russian fighter aircraft painted on the concrete. Such paintings have also been observed across at least 12 more Russian air bases ...
- Russia's aircraft decoy strategy fails to fool Ukrainian intelligence
Russia has been forced to implement a number of decoy and deception techniques in an attempt to obfuscate successful Ukrainian strikes on military locations, according to the latest British ...
- Clinical trials aim to tackle COVID-19, with nasal spray vaccine and ‘cytokine storm’ blood filtering system
“As soon as the COVID-19 pandemic began, we focused on helping address the urgent needs for therapies and a vaccine strategy,” said ... and antibody-like decoys that bind to the cytokines ...
- 4 Financial Strategies for Women During the Coronavirus Pandemic
In general, none of these strategies are a cure-all. But they're a start. And there's some small comfort. The coronavirus pandemic has shed light on the supports women – and all workers – need ...
Go deeper with Google Headlines on:
Coronavirus decoy strategy
[google_news title=”” keyword=”coronavirus decoy strategy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Heparin
- Excess Unfractionated Heparin Dosing for STEMI and NSTEMI
For patients with either NSTEMI or STEMI, American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend that intravenous unfractionated heparin (UFH) be dosed by weight ...
- Treatment Options for Heparin-Induced Thrombocytopenia
Appropriate management, as well as efficacy and safety, of heparin-induced thrombocytopenia (HIT) and prevention of severe consequences with argatroban and lepirudin are discussed. Heparin-induced ...
- Intergard Heparin Grafts from Maquet
As a highly potent, natural anticoagulant, heparin is well known as an antithrombotic agent, and it has been shown to inhibit smooth muscle cell proliferation. INTERGARD Heparin grafts incorporate ...
- Michael Strahan's Daughter Isabella Had a Perfect Response to Fan Asking If She's 'Still Alive' Amid Brain Tumor Treatment
The video, which Isabella captioned, "crazi comment," came in response to a comment from someone who wrote, "are you still alive." In the comment section of her response video, one of Isabella's ...
- Michael Strahan’s Daughter Isabella, 19, Shows Off Basket of Cancer Medications 'I Take to Stay Alive'
Isabella Strahan — the 19-year-old daughter of Michael Strahan — recently underwent her second round of chemotherapy after being diagnosed with a brain tumor ...
Go deeper with Google Headlines on:
Heparin
[google_news title=”” keyword=”Heparin” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]